Summary

The cervical cancer treatment market is expected to grow from US$ 9.43 billion in 2022 to US$ 14.07 billion by 2030; it is anticipated to record a CAGR of 5.13% from 2022 to 2030.

Cervical cancer refers to the cancer that occurs in the cells of the cervix i.e. the lower part of the uterus that connects to the vagina. In 90% of the cases, cervical malignancies occur due to the HPV infection and are diagnosed through smear screening. The increasing prevalence of cervical cancer and the rise in HPV infections are the key factors driving the cervical cancer treatment market growth. However, the lack of awareness about the diagnosis and treatment methods hampers the market's growth. Cervical cancer treatment market trends include the strong R&D from key players for cervical cancer diagnosis and drugs in cervical cancer treatment.

Increasing Prevalence of Cervical Cancer Fuel Cervical Cancer Treatment Market Growth.

Cancer has emerged as a leading cause of death worldwide. According to the World Health Organization (WHO), cancer was the first leading cause of death in people of age below 70 years in 183 countries and the fourth leading cause of death in 123 countries worldwide in 2019. In addition, according to data published by the WHO in March 2021, ~10 million deaths occurred in 2020 due to different cancer types. The market under consideration has shown significant expansion, which can be linked to the rising frequency of cervical cancer among women worldwide. According to the World Health Organization (WHO), cervical cancer kills more than 270,000 women each year. Cervical cancer mortality rates are greater in poorer nations due to the late discovery of the disease. The market is predicted to rise due to the increasing acceptance of cervical cancer diagnostic tests for the early detection of cervical cancer.

The increasing prevalence of cervical cancer has created a burden on the healthcare systems across the world. According to the International Agency for Research on Cancer (IARC), the global burden of new cancer cases is estimated to reach ~ 27.5 million by 2040, and the disease is likely to be a cause of ~163 million deaths by that year. Factors such as lifestyle changes, smoking, reduced physical activities, and uncertain health and climatic conditions are likely to lead to an even greater burden of cancer in the world in the coming years. Therefore, controlling and preventing the increasing number of cancers worldwide is essential.

Various governments have initiated programs and initiatives to increase cancer treatment and preventive measures. For instance 2017, the World Health Assembly approved the Resolution Cancer (WHA70.12), an integrated approach to preventing and controlling cancer. The program has been appealing to the WHO and various governments to accelerate their efforts to achieve the targets that are specified in the Global Action Plan (2013–2020) for the prevention and control of noncommunicable diseases (NCDs) as well as in the 2030 UN Agenda for Sustainable Development to reduce early deaths from cancer. In addition, various private organizations have joined the action plans to prevent the increasing burden of cancer, which is creating a demand for better preventive measures against the disease. Thus, the increasing prevalence of cervical cancer has accelerated the demand for new and effective therapeutic approaches, such as neoantigens, which is boosting the growth of the market.

The lack of awareness about cervical cancer among populations, healthcare providers, and policymakers, limited access to high-quality healthcare services and cervical screening programs, and a lack of functional referral systems are among the factors leading to the high incidence and mortality from cervical cancer. Cervical cancer incidence and mortality have lowered in industrialized countries owing to improved access to cytological screening and rapid treatment of early cervical lesions. It is critical to implement population-based cervical screening and increase its acceptance in low- and middle-income countries (LMICs) to reduce cervical cancer mortality. Raising awareness about risk factors such as first sexual intercourse at a young age and having multiple male sexual partners; high risk associated with the HPV types 8, 9, and 10; first full-term pregnancy at a young age; prolonged use of oral contraceptives; and HIV infections may help boost participation in screening programs. Better awareness regarding the symptoms of cervical cancer, such as intermenstrual vaginal bleeding, postmenopausal vaginal bleeding, post-coital vaginal bleeding, foul vaginal discharge, and lower abdomen pain, might help women seek early help. Nevertheless, the lack of awareness about cervical cancer among populations hinders the cervical cancer treatment market growth.

The cervical cancer treatment market analysis has been conducted by considering the following segments based on type, product, and end user. By type, the market is classified into squamous cell carcinoma, adenosquamous carcinoma, and adenocarcinoma. Based on product, the market is divided into surgery, radiation therapy, chemotherapy, immunotherapy, and therapeutic vaccines. By end user, the market is segmented into hospitals, home care, cancer centers, and others. The geographic scope of the cervical cancer treatment market report includes North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). In 2022, North America held the largest cervical cancer treatment market share.

Based on geography, the cervical cancer treatment market is classified into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America.

North America held the largest share of the cervical cancer treatment market in 2022, In North America, the US holds a significant share of the market. A vast number of R&D activities primarily drives the market's growth in the country; financial aids by governments other private and non-private organizations, collaborations within pharmaceuticals and technology companies, and increasing prevalence of neurological diseases in the country. Additionally, increasing the active participation of the government organizations in enhancing the testing procedures is expected to boost the market during the forecast period. Furthermore, the implementation of regulatory policies for rare diseases is likely to offer a significant opportunity for the market's growth during the forecast period. For instance, the American Cancer Society (ACS) in September 2020 updated the guidelines for cervical cancer screening. Thus such active involvement organization is expected to support the market growth. Furthermore, the cervical cancer treatment market analysis is carried out by identifying and evaluating key players in the market across different regions.Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA) are key primary and secondary sources referred to while preparing the cervical cancer treatment market report.

ページTOPに戻る

Table of Contents

1. Introduction
1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 Market Attractiveness Analysis
3. Research Methodology
4. Cervical Cancer Treatment Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
4.3.1 List of Vendors in the Value Chain
5. Cervical Cancer Treatment Market - Key Market Dynamics
5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints
6. Cervical Cancer Treatment Market - Global Market Analysis
6.1 Cervical Cancer Treatment - Global Market Overview
6.2 Cervical Cancer Treatment - Global Market and Forecast to 2030
7. Cervical Cancer Treatment Market – Revenue Analysis (USD Million) – By Type, 2020-2030
7.1 Overview
7.2 Adenocarcinoma
7.3 Adenosquamous carcinoma
7.4 Squamous cell carcinoma
8. Cervical Cancer Treatment Market – Revenue Analysis (USD Million) – By Product, 2020-2030
8.1 Overview
8.2 Gardasil/Gardasil 9
8.3 Cervarix
8.4 Avastin
8.5 Keytruda
8.6 Others
9. Cervical Cancer Treatment Market – Revenue Analysis (USD Million) – By Distribution Channel, 2020-2030
9.1 Overview
9.2 Hospital Pharmacies
9.3 Retail Pharmacies
9.4 Online Pharmacies
10. Cervical Cancer Treatment Market - Revenue Analysis (USD Million), 2020-2030 – Geographical Analysis
10.1 North America
10.1.1 North America Cervical Cancer Treatment Market Overview
10.1.2 North America Cervical Cancer Treatment Market Revenue and Forecasts to 2030
10.1.3 North America Cervical Cancer Treatment Market Revenue and Forecasts and Analysis - By Type
10.1.4 North America Cervical Cancer Treatment Market Revenue and Forecasts and Analysis - By Product
10.1.5 North America Cervical Cancer Treatment Market Revenue and Forecasts and Analysis - By Distribution Channel
10.1.6 North America Cervical Cancer Treatment Market Revenue and Forecasts and Analysis - By Countries
10.1.6.1 United States Cervical Cancer Treatment Market
10.1.6.1.1 United States Cervical Cancer Treatment Market, by Type
10.1.6.1.2 United States Cervical Cancer Treatment Market, by Product
10.1.6.1.3 United States Cervical Cancer Treatment Market, by Distribution Channel
10.1.6.2 Canada Cervical Cancer Treatment Market
10.1.6.2.1 Canada Cervical Cancer Treatment Market, by Type
10.1.6.2.2 Canada Cervical Cancer Treatment Market, by Product
10.1.6.2.3 Canada Cervical Cancer Treatment Market, by Distribution Channel
10.1.6.3 Mexico Cervical Cancer Treatment Market
10.1.6.3.1 Mexico Cervical Cancer Treatment Market, by Type
10.1.6.3.2 Mexico Cervical Cancer Treatment Market, by Product
10.1.6.3.3 Mexico Cervical Cancer Treatment Market, by Distribution Channel
Note - Similar analysis would be provided for below mentioned regions/countries

10.2 Europe
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 Spain
10.2.5 United Kingdom
10.2.6 Rest of Europe
10.3 Asia-Pacific
10.3.1 Australia
10.3.2 China
10.3.3 India
10.3.4 Japan
10.3.5 South Korea
10.3.6 Rest of Asia-Pacific
10.4 Middle East and Africa
10.4.1 South Africa
10.4.2 Saudi Arabia
10.4.3 U.A.E
10.4.4 Rest of Middle East and Africa
10.5 South and Central America
10.5.1 Brazil
10.5.2 Argentina
10.5.3 Rest of South and Central America
11. Industry Landscape
11.1 Mergers and Acquisitions
11.2 Agreements, Collaborations, Joint Ventures
11.3 New Product Launches
11.4 Expansions and Other Strategic Developments
12. Competitive Landscape
12.1 Heat Map Analysis by Key Players
12.2 Company Positioning and Concentration
13. Cervical Cancer Treatment Market - Key Company Profiles
13.1 F. Hoffmann-La Roche Ltd
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
Note - Similar information would be provided for below list of companies

13.2 Merck Sharp and Dohme Corp.
13.3 GlaxoSmithKline plc.
13.4 Genentech, Inc.
13.5 Amgen Inc.
13.6 Advaxis, Inc.
13.7 Biocon
13.8 Allergan, Inc
13.9 Pfizer Inc
13.10 AstraZeneca
14. Appendix
14.1 Glossary
14.2 About The Insight Partners
14.3 Market Intelligence Cloud